Evidence map›Paper›PMID 39683906›Full record

ReviewMolecules (Basel, Switzerland)2024

Perspectives on Applications of

Qingxin Li, CongBao Kang

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. NMR Studies on Protein-Ligand Interactions.International journal of molecular sciences · 2026
    Review
  2. Halogen bonds between ligands and proteins: Can we use them in validation?Protein science : a publication of the Protein Society · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Qingxin LiGuangdong Provincial Engineering Laboratory of Biomass High Value Utilization, Institute of Biological and Medical Engineering, Guangdong Academy of Sciences, Guangzhou 510316, China.ORCID 0000-0001-7460-9546
CongBao KangExperimental Drug Development Centre (EDDC), Agency for Science, Technology and Research (A*STAR), 10 Biopolis Road, #05-01, Singapore 138670, Singapore.ORCID 0000-0002-9886-9374

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fragment-based drug discovery is a powerful approach in drug discovery, applicable to a wide range of targets. This method enables the discovery of potent compounds that can modulate target functions, starting from fragment compounds that bind weakly to the targets. While biochemical, biophysical, and cell-based assays are commonly used to identify fragments,

Indexed as

Drug DiscoveryFluorineMagnetic Resonance SpectroscopyHumansLigandsProteinsRNASmall Molecule LibrariesFluorineLigandsProteinsRNASmall Molecule Libraries19F-NMRdrug discoveryfragment-based drug designfragment screeningin-cell 19F-NMR

Identifiers

PMID39683906
PMCPMC11643073

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.